Duran i Reynals Hospital

Recent papers from Duran i Reynals Hospital

1. Neonatal‐onset developmental and epileptic encephalopathy: High genetic yield and long‐term outcomes in a multicenter southern European cohortEpilepsia Open · 2026
2. HCT ‐ FS ‐Defined Frailty Is Associated With Lower Survival Across Diverse Hematologic Diagnoses After Allogeneic TransplantationEuropean Journal Of Haematology · 2026
3. Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotinSupportive Care in Cancer · 2026
4. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet · 2000
5. Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) – A Trial in ProgressOncoTargets and Therapy · 2026
6. Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaAdvances in Therapy · 2026
7. Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial ProtocolBiomedicines · 2026
8. Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor eraBritish Journal of Haematology · 2026
9. Worldwide Innovative Network Consortium: Building a Common Global Cancer DatabaseJCO Global Oncology · 2026
10. Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancerESMO Open · 2026
11. Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT ‐ SAAWP RACE StudyAmerican Journal of Hematology · 2026
12. Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working PartyHaematologica · 2026
13. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summaryFuture Oncology · 2026
14. 79P Indirect treatment comparisons of durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab + olaparib vs pembrolizumab + CP followed by pembrolizumab and vs dostarlimab + CP followed by dostarlimab as first-line treatment for mismatch repair-proficient endometrial cancerESMO Open · 2026
15. 126P Therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi) in advanced epithelial ovarian cancer (EOC)ESMO Open · 2026
16. Use of mesenchymal stromal cells derived from the Wharton’s jelly of human umbilical cord for treating patients with steroid-resistant graft versus host disease: predicting clinical response by a validated immunopotency assayScientific Reports · 2026
17. Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencingHemaSphere · 2026
18. Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaHemaSphere · 2026
19. Review of Haematological Toxicities in Well-Differentiated Neuroendocrine Tumours: A Case Report and Comprehensive Review of the LiteratureJournal of Clinical Medicine · 2026
20. Progressive Encephalomyelitis with Rigidity and Myoclonus with Glycine Receptor Antibodies (P4-2.001)Neurology · 2026